EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 / Numéro 1 (Janvier 2020) Med Sci (Paris), 36 1 (2020) 31-37 Références
Open Access
Numéro
Med Sci (Paris)
Volume 36, Numéro 1, Janvier 2020
Page(s) 31 - 37
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2019266
Publié en ligne 4 février 2020
  1. Lévy-BruhlD.Bases des recommandations vaccinales. Med/Sci (Paris) 2007 ; 23 : 404–408. [Google Scholar]
  2. Lévy-BruhlD. Estimation de l’impact épidémiologique des niveaux de couverture vaccinale insuffisants en France. Bull Acad Natle Med 2016 ; 200 : 219–231. [Google Scholar]
  3. RappuoliR, SantoniA, MantovaniA Vaccines: an achievement of civilization, a human right, our health insurance for the future. J Exp Med 2019 ; 216 : 7–9. [CrossRef] [PubMed] [Google Scholar]
  4. PlotkinSA Complex correlates of protection after vaccination. Clin Infect Dis 2013 ; 56 : 1458–1465. [CrossRef] [PubMed] [Google Scholar]
  5. ZimmermannP, CurtisN Factors that influence the immune response to vaccination. Clin Microbiol Rev 2019 ; 32 : e00084–e00018. [PubMed] [Google Scholar]
  6. McCullersJA, HuberVC Correlates of vaccine protection from influenza and its complications. Hum Vaccin Immunother 2012 ; 8 : 34–44. [CrossRef] [PubMed] [Google Scholar]
  7. HobsonD, CurryRL, BeareAS, Ward-GardnerA The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972 ; 70 : 767–777. [PubMed] [Google Scholar]
  8. CoudevilleL, BailleuxF, RicheB et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med Res Methodol 2010 ; 10 : 18. [CrossRef] [PubMed] [Google Scholar]
  9. RimmelzwaanGF, FouchierRA, OsterhausAD Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr Opin Biotechnol 2007 ; 18 : 529–536. [Google Scholar]
  10. TestaJS, ShettyV, HafnerJ et al. MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. PLoS One 2012 ; 7 : e48484. [CrossRef] [PubMed] [Google Scholar]
  11. McMichaelAJ, GotchFM, NobleGR, BearePA Cytotoxic T-cell immunity to influenza. N Engl J Med 1983 ; 309 : 13–17. [Google Scholar]
  12. McElhaneyJE, XieD, HagerWD et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006 ; 176 : 6333–6339. [CrossRef] [PubMed] [Google Scholar]
  13. LinJ, SomanathanS, RoyS et al. Lung homing CTLs and their proliferation ability are important correlates of vaccine protection against influenza. Vaccine 2010 ; 28 : 5669–5675. [CrossRef] [PubMed] [Google Scholar]
  14. BonduelleO, YahiaN, SiberilS et al. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. J Immunol 2013 ; 191 : 623–631. [CrossRef] [PubMed] [Google Scholar]
  15. PanCH, ValsamakisA, ColellaT et al. Inaugural article: modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A 2005 ; 102 : 11581–11588. [CrossRef] [PubMed] [Google Scholar]
  16. FletcherHA Correlates of immune protection from tuberculosis. Curr Mol Med 2007 ; 7 : 319–325. [CrossRef] [PubMed] [Google Scholar]
  17. PlotkinSA Is there a formula for an effective CMV vaccine?. J Clin Virol 2002 ; 25 : S13–S21. [Google Scholar]
  18. MatzingerP. The danger model: a renewed sense of self. Science 2002 ; 296 : 301–305. [Google Scholar]
  19. AkiraS, UematsuS, TakeuchiO Pathogen recognition and innate immunity. Cell 2006 ; 124 : 783–781. [CrossRef] [PubMed] [Google Scholar]
  20. PulendranB, LiS, NakayaHI Systems vaccinology. Immunity 2010 ; 33 : 516–529. [CrossRef] [PubMed] [Google Scholar]
  21. PulendranB, AhmedR Translating innate immunity into immunological memory: Implications for vaccine development. Cell 2006 ; 124 : 849–863. [PubMed] [Google Scholar]
  22. CombadiereB, LiardC Transcutaneous and intradermal vaccination. Hum Vaccin 2011 ; 7 : 811–827. [CrossRef] [PubMed] [Google Scholar]
  23. CamilloniB, BasileoM, ValenteS et al. Immunogenicity of intramuscular MF59- adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccin Immunother 2015 ; 11 : 553–563. [CrossRef] [PubMed] [Google Scholar]
  24. BoonnakK, DhitavatJ, ThantamnuN et al. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine 2017 ; 35 : 7339–7346. [CrossRef] [PubMed] [Google Scholar]
  25. ZweerinkHJ, CourtneidgeSA, SkehelJJ et al. Cytotoxic T cells kill influenza virus infected cells but do not distinguish between serologically distinct type A viruses. Nature 1977 ; 267 : 354–356. [Google Scholar]
  26. LiardC, MunierS, AriasM et al. Targeting of HIV-p24 particlebased vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 2011 ; 29 : 6379–6391. [CrossRef] [PubMed] [Google Scholar]
  27. RomaniN, FlacherV, TrippCH et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol 2012 ; 351 : 113–138. [PubMed] [Google Scholar]
  28. DuffyD, PerrinH, AbadieV et al. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T Cells. Immunity 2012 ; 37 : 917–929. [CrossRef] [PubMed] [Google Scholar]
  29. VogtA, CombadiereB, HadamS et al. 40nm, but not 750 or 1,500nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006 ; 126 : 1316–1322. [CrossRef] [PubMed] [Google Scholar]
  30. Haidari G, Cope A, Miller A, et al. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial. Sci Rep 2017; 7. [Google Scholar]
  31. CheesemanHM, DayS, McFarlaneLR et al. Combined skin and muscle DNA priming provides enhanced humoral responses to a human immunodeficency virus type 1 clade C envelope vaccine. Hum Gene Ther 2018 ; 29 : 1011–1028. [Google Scholar]
  32. MaheB, VogtA, LiardC et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol 2009 ; 129 : 1156–1164. [CrossRef] [PubMed] [Google Scholar]
  33. CombadièreB, VogtA, MahéB et al. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated Influenza vaccine: a randomized phase I trial. PLoS One 2010 ; 5 : e10818. [CrossRef] [PubMed] [Google Scholar]
  34. LevinC, BonduelleO, NuttensC et al. Critical role for skin-derived migratory DCs and Langerhans cells in TFH and GC responses after intradermal immunization. J Invest Dermatol 2017 ; 137 : 1905–1913. [CrossRef] [PubMed] [Google Scholar]
  35. GonçalvesE, BonduelleO, SoriaA et al. Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination. J Clin Invest 2019 ; 129 : 1960–1971. [CrossRef] [PubMed] [Google Scholar]
  36. VogtA, MaheB, CostagliolaD et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans. J. Immunol 2008 ; 180 : 1482–1489. [CrossRef] [PubMed] [Google Scholar]
  37. LiardC, MunierS, Joulin-GietA et al. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol 2012 ; 132 : 615–625. [CrossRef] [PubMed] [Google Scholar]
  38. HainingWN, PulendranB Identifying gnostic predictors of the vaccine response. Curr Opin Immunol 2012 ; 24 : 332–336. [CrossRef] [PubMed] [Google Scholar]
  39. RaoS, GhoshD, AsturiasEJ, WeinbergA What can we learn about influenza infection and vaccination from transcriptomics?. Hum Vaccines Immunother 2019 ; 0 : 1–9. [Google Scholar]
  40. BucasasKL, FrancoLM, ShawCA et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011 ; 203 : 921–929. [PubMed] [Google Scholar]
  41. NakayaHI, WrammertJ, LeeEK et al. Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 2011 ; 12 : 786–795. [CrossRef] [PubMed] [Google Scholar]
  42. Marchetti L, Siena E, Lauria M, et al. Exploring the limitations of peripheral blood transcriptional biomarkers in predicting influenza vaccine responsiveness. Complexity 2017. https://doi.org/10.1155/2017/3017632. [Google Scholar]
  43. RechtienA, RichertL, LorenzoH et al. Systems vaccinology identifies an early innate immune signature as a correlate of antibody responses to the Ebola vaccine rVSV-ZEBOV. Cell Rep 2017 ; 20 : 2251–2261. [CrossRef] [PubMed] [Google Scholar]
  44. TsangJS Utilizing population variation, vaccination, and systems biology to study human immunology. Trends Immunol 2015 ; 36 : 479–493. [CrossRef] [PubMed] [Google Scholar]
  45. ColeKS, MartinJM, HorneWT et al. Differential gene expression elicited by children in response to the 2015–16 live attenuated versus inactivated influenza vaccine. Vaccine 2017 ; 35 : 6893–6897. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.